Jaguar Health, Inc. (JAGX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
JAGX Revenue Growth
Revenue Breakdown (FY 2025)
JAGX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
JAGX Revenue Analysis (2014–2025)
As of May 8, 2026, Jaguar Health, Inc. (JAGX) generated trailing twelve-month (TTM) revenue of $11.5 million, reflecting moderate decline in growth of -7.8% year-over-year. The most recent quarter (Q4 2025) recorded $3.2 million in revenue, up 4.9% sequentially.
Looking at the longer-term picture, JAGX's 5-year compound annual growth rate (CAGR) stands at +4.2%, indicating moderate growth over time. The company achieved its highest annual revenue of $12.0 million in 2022.
Revenue diversification analysis shows JAGX's business is primarily driven by Mytesi (98%), License (2%), and Neonorm (0%). With over half of revenue concentrated in Mytesi, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PRGO (-3.6% YoY), PAHC (+32.4% YoY), and SUPN (+16.3% YoY), JAGX has underperformed the peer group in terms of revenue growth. Compare JAGX vs PRGO →
JAGX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| JAGXCurrent | $12M | -7.8% | +4.2% | -398.8% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 PAHC | $1.3B | +32.4% | +10.1% | 8.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 IRWD | $296M | +13.8% | -5.3% | 40.1% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
JAGX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $11.5M | -1.5% | $7.7M | 67.2% | $-45,908,000 | -398.8% |
| 2024 | $11.7M | +19.8% | $9.7M | 83.3% | $-30,831,000 | -263.8% |
| 2023 | $9.8M | -18.4% | $7.7M | 79.1% | $-34,291,000 | -351.3% |
| 2022 | $12.0M | +175.8% | $9.9M | 83.1% | $-34,415,000 | -287.8% |
| 2021 | $4.3M | -53.8% | $2.0M | 46.2% | $-40,708,000 | -939.1% |
| 2020 | $9.4M | +62.5% | $6.1M | 65.1% | $-26,647,000 | -283.9% |
| 2019 | $5.8M | +30.8% | $2.0M | 33.9% | $-28,948,000 | -501.3% |
| 2018 | $4.4M | +1.3% | $1.7M | 37.4% | $-30,823,968 | -698.0% |
| 2017 | $4.4M | +2981.6% | $3.5M | 79.8% | $-34,247,060 | -785.3% |
| 2016 | $142K | -45.2% | $90K | 63.3% | $-13,585,985 | -9599.8% |
See JAGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JAGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JAGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJAGX — Frequently Asked Questions
Quick answers to the most common questions about buying JAGX stock.
Is JAGX's revenue growth accelerating or slowing?
JAGX revenue declined -7.8% year-over-year, contrasting with the 5-year CAGR of +4.2%. TTM revenue fell to $12M. This reverses the prior growth trend.
What is JAGX's long-term revenue growth rate?
Jaguar Health, Inc.'s 5-year revenue CAGR of +4.2% reflects the variable expansion pattern. Current YoY growth of -7.8% is below this long-term average.
How is JAGX's revenue distributed by segment?
JAGX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.